CRBP - CIK 0001595097
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported net income of -$78.54M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$78.54M | -95.3% |
| FY 2024 | -$40.21M | +9.9% |
| FY 2023 | -$44.60M | -5.3% |
| FY 2022 | -$42.35M | +7.2% |
| FY 2021 | -$45.64M | +59.0% |
| FY 2020 | -$111.27M | -55.7% |
| FY 2019 | -$71.45M | -28.3% |
| FY 2018 | -$55.67M | -71.7% |
| FY 2017 |
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported net income of -$78.54M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, Corbus Pharmaceuticals Holdings, Inc.'s net income declined from -$602.35K to -$78.54M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$32.42M |
| -62.1% |
| FY 2016 | -$20.00M | -126.0% |
| FY 2015 | -$8.85M | -248.4% |
| FY 2014 | -$2.54M | -321.8% |
| FY 2013 | -$602.35K | - |